Schrödinger, Inc. (SDGR) Bundle
A Brief History of Schrödinger, Inc. (SDGR)
Company Overview
Founded in 1990, Schrödinger, Inc. is a technology company that provides a platform for molecular modeling and simulation. The company has established itself as a leader in the field of computational chemistry and drug discovery.
Initial Public Offering (IPO)
Schrödinger went public on February 5, 2020. The company raised approximately $200 million through its IPO, offering 10 million shares at a price of $20 per share.
Financial Performance
As of the end of 2022, Schrödinger reported revenues of $91.3 million, up from $70.1 million in 2021.
| Year | Revenue ($ million) | Net Income ($ million) | Total Assets ($ million) | Market Capitalization ($ billion) |
|---|---|---|---|---|
| 2020 | $57.3 | ($24.4) | $115.2 | $1.7 |
| 2021 | $70.1 | ($12.1) | $143.4 | $2.1 |
| 2022 | $91.3 | ($5.9) | $187.5 | $2.9 |
Recent Developments
In 2023, Schrödinger announced several strategic partnerships aimed at advancing its drug discovery platform. The collaborations include contracts with major pharmaceutical companies, leading to potential revenue growth exceeding $200 million over the next five years.
Technological Innovations
The company is known for its proprietary software, which utilizes advanced algorithms for molecular modeling. This software is integral in various stages of drug discovery and development.
| Innovation | Year Introduced | Impact |
|---|---|---|
| Schrödinger Suite | 2004 | Accelerated drug design processes |
| Live Design | 2017 | Real-time virtual screening |
| AI-driven docking | 2021 | Improved accuracy in binding predictions |
Acquisitions and Partnerships
Schrödinger has engaged in various acquisitions to bolster its technological capabilities. In 2021, the company acquired a biotech firm for approximately $40 million, enhancing its drug development pipeline.
- Acquisition of Biotech Company, 2021
- Partnership with Major Pharma, 2022
- Collaboration with Academia, 2023
Stock Performance
As of October 2023, Schrödinger's stock price stood at approximately $22.50 per share, reflecting a market capitalization of around $1.2 billion.
Industry Position
Schrödinger competes with other well-known players in the biotech and pharmaceutical sectors, including:
- Atomwise
- Exscientia
- Insilico Medicine
Conclusion on Growth Potential
The growth potential of Schrödinger, Inc. is significant, with projections estimating a compound annual growth rate (CAGR) of 15% over the next five years.
A Who Owns Schrödinger, Inc. (SDGR)
Major Shareholders
The ownership of Schrödinger, Inc. is divided among several key institutional and individual investors.
| Shareholder Type | Name | Ownership Percentage | Number of Shares |
|---|---|---|---|
| Institutional Investor | Vanguard Group, Inc. | 9.72% | 1,963,118 |
| Institutional Investor | BlackRock, Inc. | 9.23% | 1,854,126 |
| Institutional Investor | FMR LLC (Fidelity) | 7.41% | 1,507,474 |
| Institutional Investor | Wellington Management Co. LLP | 6.34% | 1,280,626 |
| Individual Investor | James C. McNerney, Jr. | 4.15% | 842,476 |
Insider Ownership
Insider ownership in Schrödinger, Inc. reflects the management's confidence in the company.
| Insider Name | Position | Ownership Percentage | Number of Shares |
|---|---|---|---|
| David M. E. McCarthy | CEO | 1.20% | 242,017 |
| Sandeep Gulati | President | 0.80% | 162,634 |
| Maximilian F. von Schaefer | CFO | 0.45% | 91,530 |
| D. J. D. Zhang | Chief Scientist | 0.35% | 70,193 |
Market Capitalization
As of October 2023, Schrödinger, Inc. has a market capitalization of approximately $1.9 billion.
Stock Performance
The stock performance of Schrödinger, Inc. over the past year shows fluctuations in price.
| Period | Stock Price ($) | Change (%) |
|---|---|---|
| 1-Year High | 40.00 | +15.00% |
| 1-Year Low | 22.50 | -20.00% |
| Current Price | 33.50 | -5.00% |
Recent Financial Figures
Recent financial performance of Schrödinger, Inc. indicates a growing revenue stream.
| Fiscal Year | Revenue ($ Million) | Net Income ($ Million) | R&D Expenses ($ Million) |
|---|---|---|---|
| 2023 | 125.4 | -20.3 | 55.2 |
| 2022 | 110.7 | -15.1 | 50.0 |
| 2021 | 90.5 | -12.5 | 45.3 |
Conclusion on Ownership Structure
The ownership structure of Schrödinger, Inc. is a combination of institutional investors, insider stakeholders, and market dynamics that shape its financial landscape.
Schrödinger, Inc. (SDGR) Mission Statement
Schrödinger, Inc. operates under a mission that aims to enhance the development of therapeutics and materials through a computational platform that combines physics-based simulations and machine learning. The company strives to revolutionize drug discovery processes and material science by providing sophisticated software solutions.
Corporate Vision
Schrödinger envisions a future where advanced technology accelerates the pace of scientific innovation. The emphasis is placed on integrating cutting-edge computational methods to streamline research across various fields.
Core Values
- Innovation: Commitment to continuous improvement and groundbreaking discoveries.
- Collaboration: Fostering partnerships with academic and industry leaders.
- Integrity: Upholding transparency and ethical scientific practices.
- Diversity: Promoting an inclusive workplace that values varied perspectives.
Business Model
The business model of Schrödinger combines software licensing, collaborations with pharmaceutical companies, and internal research initiatives. The generated revenue has shown consistent growth, reflecting the increasing demand for computational tools in the life sciences sector.
Financial Overview
As of the fiscal year 2022, Schrödinger reported:
| Metric | 2022 Amount | 2021 Amount |
|---|---|---|
| Total Revenue | $148.6 million | $96.2 million |
| Net Loss | ($42.9 million) | ($31.8 million) |
| R&D Expenses | $81.7 million | $63.1 million |
| Cash and Cash Equivalents | $129.2 million | $156.3 million |
| Market Capitalization | $1.48 billion | $2.57 billion |
Strategic Goals
Schrödinger's strategic goals include:
- Enhancing the capability and accessibility of their computational platform.
- Expanding partnerships with biopharmaceutical companies.
- Investing in innovative research projects in the realm of drug discovery.
- Increasing market presence internationally.
Long-term Objectives
The long-term objectives are set to foster sustainable growth by:
- Developing new software features for improved user experience.
- Entering emerging markets to tap into new opportunities.
- Increasing the pipeline of proprietary drug candidates.
- Aiming for strategic acquisitions to bolster technological expertise.
Recent Milestones
In 2023, Schrödinger reached several significant milestones including:
- Announcing a collaboration with a major pharma company valued at $50 million.
- Releasing a new version of their software platform, featuring enhanced machine learning algorithms.
- Publishing over 100 peer-reviewed research papers leveraging their technology.
Conclusion Remarks
The mission statement of Schrödinger, Inc. reflects its commitment to driving innovation in the life sciences through computational power, collaboration, and a focus on sustainable practices. Through continuous development and strategic partnerships, the company seeks to redefine the boundaries of drug discovery and material science.
How Schrödinger, Inc. (SDGR) Works
Business Model
Business Model
Schrödinger, Inc. operates primarily within the biotechnology sector, focusing on software solutions that enhance drug discovery and materials science through computational modeling. The company uses its proprietary software platform to simulate molecular interactions, accelerating the process of drug development.
Revenue Streams
- Software Licenses
- Collaborative Research Agreements
- Consulting Services
In 2022, Schrödinger reported total revenue of approximately $108 million, marking a year-over-year increase of 33% compared to 2021.
Financial Performance
The financial performance of Schrödinger, Inc. is as follows:
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Total Revenue | $108 million | $81 million | $66 million |
| Net Income | -$26 million | -$24 million | -$22 million |
| Operating Expenses | $75 million | $59 million | $50 million |
| Cash and Cash Equivalents | $200 million | $179 million | $160 million |
Research and Development
Schrödinger invests heavily in R&D to enhance its software capabilities and expand its applications in drug discovery. In 2022, R&D expenses were reported at approximately $50 million, representing nearly 46% of total revenue.
Key Partnerships
- Collaboration with Amgen for drug discovery efforts
- Partnership with Bristol-Myers Squibb for oncology research
- Joint ventures with various academic institutions for research purposes
Market Position
As of mid-2023, Schrödinger, Inc. holds a market capitalization of approximately $2.4 billion. The company competes with other biotech firms utilizing computational chemistry, such as:
- Thermo Fisher Scientific Inc.
- Peptidream Inc.
- Evotec SE
Stock Performance
Schrödinger, Inc.'s stock performance has experienced fluctuations, with a 52-week range of $10.77 to $31.65, as of October 2023. The stock price was approximately $23.50 on October 1, 2023.
Challenges and Opportunities
Schrödinger faces challenges such as the high competition in drug discovery technology and the need for continuous innovation. However, opportunities exist in expanding its software applications into new therapeutic areas and increased collaborations with pharmaceutical companies.
Future Outlook
Analysts project a positive outlook for Schrödinger, with expected revenue growth of 25% in 2023, driven by an increase in software licensing and strategic partnerships.
How Schrödinger, Inc. (SDGR) Makes Money
Revenue Streams
Schrödinger, Inc. generates revenue through multiple channels, primarily involving software licensing and drug discovery collaborations.
Software Licensing
The company provides powerful computational software for materials science and drug discovery applications. In 2022, Schrödinger reported approximately $69.7 million in revenue from software licensing.
Collaborative Research Agreements
Schrödinger engages in collaborative research agreements with pharmaceutical and biotech companies. For instance, in 2022, the company recognized about $57.4 million from collaboration agreements.
Development Partnerships
In addition to direct collaborations, Schrödinger partners with other organizations for drug development initiatives. This includes agreements with major pharmaceutical companies, contributing significantly to their revenue. In 2022, revenue from these partnerships was around $20.5 million.
Table: Schrödinger, Inc. Revenue Breakdown (2022)
| Revenue Source | Amount (in millions) |
|---|---|
| Software Licensing | $69.7 |
| Collaborative Agreements | $57.4 |
| Development Partnerships | $20.5 |
| Total Revenue | $147.6 |
Cost Structure and R&D Investments
Schrödinger invests significantly in research and development (R&D) to enhance its software capabilities and support drug discovery. In 2022, R&D expenses amounted to approximately $110.2 million.
Operational Expenses
Operational costs include salaries, software development, and administrative expenses. In 2022, total operational expenses were around $134.5 million.
Table: Schrödinger, Inc. Expense Breakdown (2022)
| Expense Category | Amount (in millions) |
|---|---|
| Research & Development | $110.2 |
| Operational Expenses | $134.5 |
| Total Expenses | $244.7 |
Strategic Growth Initiatives
Schrödinger continuously seeks to expand its capabilities through strategic partnerships and acquiring innovative technologies. These initiatives are expected to drive future revenue growth.
Market Position and Competitors
Schrödinger operates in a competitive landscape with companies like Relx Group and BioSymetrics. The demand for computational drug discovery tools is growing, with the global market projected to reach $4.2 billion by 2025.
Financial Health Indicators
As of Q2 2023, Schrödinger reported a cash position of approximately $392 million, providing a solid foundation for future growth and operational expenditures.
Schrödinger, Inc. (SDGR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support